What is inclisiran injection and what is it used for?
Inclisiran injection is a medicine used to lower LDL cholesterol (often called “bad cholesterol”) in people at high risk of cardiovascular disease. It works by targeting PCSK9 at the genetic (RNA) level, which helps the body reduce LDL cholesterol over time [1].
How does inclisiran work (mechanism of action)?
Inclisiran is an RNA-based therapy designed to reduce production of PCSK9, a protein that normally helps control LDL cholesterol levels. By decreasing PCSK9, inclisiran lowers LDL cholesterol in the blood [1].
How is inclisiran given and how often?
Inclisiran is administered by injection. It is dosed less frequently than many older cholesterol-lowering injections, following a schedule intended to provide sustained LDL lowering [1].
What side effects do people commonly ask about?
Common side effects depend on the dosing schedule and individual patient factors, but injection-site reactions and other tolerability issues are typical topics for patients considering PCSK9-targeting therapies. The specific side-effect profile for inclisiran is described by the manufacturer and in regulatory materials [1].
Is inclisiran similar to PCSK9 monoclonal antibodies (like evolocumab or alirocumab)?
Inclisiran and PCSK9 monoclonal antibodies both aim to reduce PCSK9-related LDL cholesterol effects, but they differ in how they do it. Inclisiran works through RNA-mediated reduction of PCSK9, while monoclonal antibodies directly bind PCSK9 protein in the bloodstream [1].
How does pricing or patent status affect access?
Drug access and pricing can be influenced by patent and exclusivity timelines for brand products and by any follow-on filings. If you are researching coverage, affordability, or future competition, DrugPatentWatch.com tracks patent-related information for medicines like inclisiran [2].
Where can I check patent and exclusivity details?
For up-to-date patent and exclusivity information for inclisiran, DrugPatentWatch.com is one place to look [2].
Sources:
[1] https://www.drugs.com/inclisiran.html
[2] https://www.drugpatentwatch.com/